文献速递腹部技术与安全US

隐匿性肝结节:超声造影的检出与特征描述

Occult liver nodules: their detection and characterization with CEUS.
PubMed 文献 · Abdom Radiol (NY) · 2025-01-18

本研究回顾性纳入100例肝癌高危患者(81例肝硬化),共114个隐匿性病灶,采用三种超声造影技术(盲打注射、门静脉期扫查、追加注射)检出并应用CEUS LI-RADS分类。CEUS可检出并特征描述隐匿结节,对临床管理有积极影响。

要点

  • MRI/CT提示异常强化但常规超声不可见的隐匿结节,可用盲打注射CEUS寻找动脉期高强化对应灶。
  • 门静脉期扫查可检出常规超声未见的廓清灶,追加注射用于评估动脉期高强化。
  • CEUS LI-RADS分类使48%(24/50)CT/MRI报告的隐匿病灶LI-RADS分级上调。

核心结论

  • 研究表明使用CEUS技术和CEUS LI-RADS算法可检出并特征描述隐匿结节,对临床管理有积极影响。

研究设计与样本

  • 回顾性研究,从存档患者日志中识别100例肝癌高危患者(81例肝硬化),均有隐匿性病灶并接受CEUS检查。
  • 采用三种专用CEUS技术:盲打注射、门静脉期全肝扫查、追加注射。

关键影像表现/征象

  • 114个隐匿病灶中78个(68%)源于MRI(n=69)或CT(n=9)观察到的异常强化,一般为动脉期高强化。
  • 其余36个(32%)隐匿病灶首次在CEUS中发现,一般为门静脉期扫查的廓清灶或偶发的动脉期高强化或邻近其他目标的廓清。
  • 所有廓清区域均行追加注射以评估动脉期高强化。

诊断标准与关键数值

  • 应用CEUS LI-RADS算法分类:26个LR-5,34个LR-4,5个LR-M。
  • CEUS使24/50(48%)CT/MRI报告的隐匿病灶LI-RADS分级上调。
  • 29个(25%)隐匿病灶接受治疗,其中LR-5和LR-M类别中5个经活检确认、15个接受治疗。
  • 来自MR/CT和CEUS两来源的12个隐匿病灶行治疗反应评估,CEUS分类为7个LR-TR viable、1个LR-TR nonviable、4个LR-TR equivocal。

临床应用与阅片要点

  • 对常规超声不可见但CT/MRI提示异常强化的结节,可尝试盲打注射CEUS寻找动脉期高强化对应灶。
  • 门静脉期全肝扫查有助于检出常规超声未见的廓清灶。
  • 对廓清区域应追加注射以评估动脉期高强化,并应用CEUS LI-RADS算法分类。
  • 目前LI-RADS不推荐由非专家对常规超声不可见结节行CEUS检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Contrast enhanced ultrasound (CEUS) now joins the ranks of CT and MRI for noninvasive diagnosis of hepatocellular carcinoma (HCC). CEUS LI-RADS provides greater than 95% specificity for diagnosis within LR-5. Unlike CT/MRI, CEUS is nodule based. Currently, LI-RADS does not recommend CEUS of nodules occult or invisible on pre-contrast ultrasound except by experts. This study addresses our ability to find occult nodules using CEUS and to characterize them with CEUS LI-RADS.

METHODS: 100 patients at risk for HCC, 81 with cirrhosis, with occult lesions were retrospectively identified from our archived patient logs. All patients had CEUS examination. Three specialized CEUS techniques (blindshot injection, portal venous (PVP) sweep of the liver, and on-top injection) are used to evaluate nodules.

RESULTS: There were 114 occult lesions in 100 patients. The origin of 78(68%) lesions was an MRI (n = 69) or CT scan (n = 9) with an observation of abnormal enhancement, generally arterial phase hyperenhancement (APHE). All these patients had blindshot CEUS injection looking for a correlate with APHE. The remainder of occult lesions (n = 36)(32%) were first detected during CEUS, generally as washout foci on PVP sweeps or incidental APHE or washout nearby other targets. All washout areas had subsequent on-top injection to assess for APHE. Application of CEUS LI-RADS algorithm categorized 26 LR-5, 34 LR-4, and 5 LR-M. CEUS upgraded LI-RADS category of 24/50(48%) occult lesions reported on CT/MRI. 29(25%) occult lesions were offered treatment and from categories LR-5 and LR-M, 5 had biopsy confirmation and 15 were treated. From both sources, MR/CT and CEUS, there were 12 occult lesions scanned for treatment response, categorized as 7 LR-TR viable, 1 LR-TR nonviable, and 4 LR-TR equivocal on CEUS.

CONCLUSION: Our study shows we can find and characterize occult nodules using CEUS techniques and CEUS LI-RADS algorithm, with positive impact on clinical management.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Qiao A, Samuel AS, Merrill C, et al. Occult liver nodules: their detection and characterization with CEUS. Abdom Radiol (NY). 2025. PMID: 39825006. doi:10.1007/s00261-024-04651-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。